NOVEL BREAKTHROUGH THERAPY FOR UNRESECTABLE LAPC: ONCOSIL™ P-32 BRACHYTHERAPY COMBINED WITH CHEMOTHERAPY

Saturday 28 November
18:15-19:15 GMT+1

Synopsis: OncoSil™ P-32 microparticles is a novel, emerging brachytherapy treatment, recently granted Breakthrough Designation in both the US and Europe, which delivers 100 Gy to the tumour in patients with LAPC. The recently completed PanCO study, which combined OncoSil™ P-32 microparticles with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy, reported a favourable toxicity profile and encouraging efficacy. Could this exciting approach expand our multi-disciplinary options and transform the prognosis for unresectable LAPC by increasing the proportion of patients reaching R0 resection?

Chair: David Turner, Adjuvantyx Ltd, Sevenoaks, United Kingdom

 

 

 

 

 

Presentation title: OncoSil system product introduction and overview
Presenter: Dr Dan Croagh, Monash Medical Centre and Jessie Macpherson Private Hospital, Australia
Dan Croagh is a hepatobiliary and pancreatic surgeon working predominantly at Monash Medical Centre and Jessie Macpherson Private Hospital.

 

 

 

 

Presentation title: Updated results of PanCO study Oncosil P-32 Microparticels in unresectable LAPC with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy
Presenter: Dr Harpreet Wasan, Hammersmith Hospital, Imperial College London, United Kingdom
Dr Harpreet Wasan leads the gastrointestinal clinical research programme at Hammersmith Hospital, Imperial College London.

 

 

 

 

Presentation title: Indirect Treatment comparison of PanCO vs Standard of care for unresectable LAPC
Presenter: Dr Harpreet Wasan, Hammersmith Hospital, Imperial College London, United Kingdom

 

Presentation title: Transforming the prognosis in unresectable LAPC: The PanCO trial resected cohort
Presenter: Dr Dan Croagh, Monash Medical Centre and Jessie Macpherson Private Hospital, Australia

 

This session is sponsored by